WCG Clinical IPO: How to Buy WCG Clinical Stock When It Goes Public

WCG Clinical, which provides ethical reviews and other clinical trial services to biopharmaceutical companies, has postponed its planned $720 million initial public offering, sources say. The offering was scheduled to wrap on Thursday, with the company poised to offer 45 million shares at a range of between $15 and $17 each.

It's not clear at this time why WCG has pumped the brakes on the deal.

We'll update this page as new information becomes available.

How to buy WCG Clinical stock when it starts trading

Once WCG Clinical goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.

Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Open your brokerage account. Complete an application with your details.
Confirm your payment details. Fund your account.
Research the stock. Find the stock by name or ticker symbol – WCGC – and research it before deciding if it's a good investment for you.
Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.

Finder's picks for buying WCG Clinical stock when it goes public

Go to site

$0 commission trading
Instant withdrawals with a 1.75% fee
Supports 250+ cryptocurrencies
High-yield account earns up to 4.40% APY

Disclaimer

Go to site

Trade options, futures, options on futures, stocks, ETFs
$0 commission to close options
Pro-grade platform and risk analysis tools

Go to site

Trade $0 commission stocks, ETFs, and options with as little as $1
After-hours trading available
Earn 4.5% interest on uninvested cash with Gold
24/7 customer support

How do similar companies perform?

It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Looking at the performance of similar companies can help you decide if now is a good time to buy WCG Clinical stock.

See how the following stocks are performing, and view details like market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield.

Company summary
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Historical performance
Stock information
- Market capitalization: $10651353088
- P/E ratio: 30.0342
- PEG ratio: 1.6301
- Dividend yield: N/A%
Get more detailed information and learn how to buy MEDP.US stock
Company summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Historical performance
Stock information
- Market capitalization: $117147672576
- PEG ratio: 1.978
- Dividend yield: 0.0433%
Get more detailed information and learn how to buy BMY.US stock
Company summary
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Historical performance
Stock information
- Market capitalization: $36298186752
- P/E ratio: 26.2454
- PEG ratio: 1.0561
- Dividend yield: N/A%
Get more detailed information and learn how to buy IQV.US stock

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

1 - 10 of 10

Product USFST	Finder Score	Available asset types	Stock trade fee	Minimum deposit	Cash sweep APY	Signup bonus
Tastytrade	Finder score 8.8 Great	Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills	$0	$0	N/A	Get $50-$5,000	Go to site View details	loading Fetching your data...
Robinhood	Finder score 9 Excellent	Stocks, Options, ETFs, Cryptocurrency	$0	$0	4.5%	Get a free stock	Go to site View details	loading Fetching your data...
SoFi Invest®	Finder score 8.2 Great	Stocks, Options, Mutual funds, ETFs, Alternatives	$0	$0	0.02%	Get up to $1,000 in stock	Go to site View details	loading Fetching your data...
OPTO	Finder score 6.2 Standard	Stocks, ETFs	$0	$0	N/A	Earn up to $300	Go to site View details	loading Fetching your data...
eToro	Finder score 8 Great	Stocks, Options, ETFs, Cryptocurrency	$0	$0	4.9%	FINDER EXCLUSIVE: Get a guaranteed $15 bonus and $10 in free crypto	Go to site View details	loading Fetching your data...
Public.com	Finder score 8.6 Great	Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account	$0	$0	4.35%	Get up to $10,000 and transfer fees covered	Go to site View details	loading Fetching your data...
Stash	Finder score 7.4 Great	Stocks, ETFs	$0	$0	0.1%	Get $10 when you sign up and deposit $5	Go to site View details	loading Fetching your data...
Wealthfront	Finder score 9 Excellent	Stocks, ETFs	$0	$500	4.00%	Get $50	Go to site View details	loading Fetching your data...
Zacks Trade	Finder score 7.6 Great	Stocks, Bonds, Mutual funds, ETFs, CDs	$0.01	$250	2.83%	Get up to $500	Go to site View details	loading Fetching your data...
M1 Finance	Finder score 8.2 Great	Stocks, ETFs, Cryptocurrency	$0	$100	4.00%	N/A	Go to site View details	loading Fetching your data...

loading

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Thank you for your feedback!

More resources on Finder

How to buy Caribou Bioscience stock (Caribou Bioscience) How to buy Snap One Holdings stock (Snap One Holdings Corp)

More guides on Finder

Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.

Ask a question

Click here to cancel reply.

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

How to buy WCG Clinical (WCGC) stock when it goes public

Here's everything we know so far about the WCG Clinical IPO.

How to buy WCG Clinical stock when it starts trading